Source: Pharamceutical Technology

NeuroNascent: Neuronascent plans Phase II Parkinson's disease trial with neurorestorative drug

The company will likely start a Phase II study in H1 2024 and raise up to $25 million in an ongoing Series A.

Read full article »
NeuroNascent's Competitors | NeuroNascent's News | NeuroNascent's Financials
Stay up-to-date with the latest news on NeuroNascent
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Judith Kelleher-Andersson's photo - President & CEO of NeuroNascent

President & CEO

Judith Kelleher-Andersson

CEO Approval Rating

86/100

Read more
Stay up-to-date with the latest news on NeuroNascent